Acupuncture for the Treatment of Postoperative Ileus After Gastrointestinal Surgery

NCT ID: NCT04713241

Last Updated: 2022-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to learn if electro-acupuncture is a feasible treatment option for postoperative ileus after abdominal surgery. The second goal of this study is to evaluate the time to resolution of postoperative ileus after receiving electro-acupuncture treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Postoperative ileus is one of the most common complications following abdominal surgery. Despite significant advances in prevention, postoperative ileus continues to be a clinical issue. For patients experiencing postoperative ileus after a bowel resection, current treatment includes bowel rest, reduction of oral diet, and possible nasogastric tube placement while waiting for the postoperative ileus to resolve. Postoperative ileus results in postoperative complications, discomfort, and increases hospital stay. Electro-acupuncture treatment could potentially expedite the return of bowel function, reducing length of stay and increasing comfort. Additionally, acupuncture has been shown to be helpful for pain and nausea management, and thus may reduce the need for opioid and anti-nausea medications.

This study includes two groups. Both groups will be treated with conservative standard care (SOC), including bowel rest with nothing by mouth (NPO) status and placement of nasogastric tube if clinically necessary. Participants in both groups will continue on SOC postoperative recovery care with early feeding and ambulation, along with minimizing opioid use.

Group A: Participants assigned to group A will receive the SOC treatment described above and will also be asked to complete questionnaires to rate their symptoms.

Group B: Participants assigned to group B will receive the SOC described above and be given a daily 20-30 minute acupuncture treatment from the time of randomization until the return

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Ileus Gastrointestinal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: SOC

Participants will receive the SOC and will also be asked to complete questionnaires to rate their symptoms

Group Type ACTIVE_COMPARATOR

Standard of Care Bowel rest

Intervention Type OTHER

Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated

Group B: Electro-Acupuncture

Participants will receive the SOC + a daily 20-30 minute electro-acupuncture treatment from the time of randomization until the return of bowel function. The first treatment will be provided within 48 hours after the diagnosis of postoperative ileus. Participants will receive acupuncture every day until normal bowel movement function returns.

Group Type EXPERIMENTAL

Electro-acupuncture

Intervention Type PROCEDURE

20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions

A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level.

Standard of Care Bowel rest

Intervention Type OTHER

Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electro-acupuncture

20-30 minute acupuncture treatment in sessions from start of study (within 48 hours of diagnosis) to return of bowel functions

A practitioner stimulates certain points on the body by placing thin needles in the skin. Electrical stimulation is then added to some of the needles. This involves placing wires on the needles, which are connected to a machine that delivers a weak electrical current through the wires. The strength of the electrical current will be changed slowly until it is at a comfortable level.

Intervention Type PROCEDURE

Standard of Care Bowel rest

Bowel rest with NPO status and placement of nasogastric tube (NGT) if clinically indicated

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements
* Diagnosis of gastrointestinal cancer
* Bowel resection was performed via an open or laparoscopic approach
* Diagnosis of POI defined as one or more of the following criteria: 1) return to NPO status after initial attempts at oral diet, and/or 2) need for placement of nasogastric tube after surgery.
* Willingness to comply with all study interventions of acupuncture

Exclusion Criteria

* Active Infection at or near the acupuncture site or systemic infection (e.g. sepsis)
* Physical deformities that could interfere with accurate acupuncture and point location
* Concurrent use of other alternative medicines such as herbal agents and high dose vitamins and minerals
* Known coagulopathy or taking heparin (including low molecular weight heparin) at full anti-coagulation doses (prophylaxis is allowed) or Coumadin at any dose. Patients on aspirin or non-steroidal anti-inflammatories or other antiplatelet medicines will be allowed to participate
* Platelets \<50 H K/UL in the past 30 days
* White Blood Cells (WBCs) \<3.0 K/UL or Absolute Neutrophil Count (ANC) \<1500 K/UL in the past 30 days
* INR \>5 in the past 30 days
* Liver failure defined as liver function test \>5x upper limit of normal
* Implanted electrical device such as a cardiac pacemaker, insulin pump or pain pump
* Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry
* Previous acupuncture treatment for any indications within 30 days of enrollment
* Currently pregnant
* Grade III lymphedema/lymphedema considered severe by the treating clinician
* Chronic daily opioid use prior to admission
* Enrollment in another surgical clinical trial
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Case Comprehensive Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Lee, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CASE3220

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.